Capping a series of investments designed to boost its manufacturing footprint, Novo Nordisk has said it will spend around $550 million to increase output in Chi 20 March 2024
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house. 19 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.